Protalix Biotherapeutics, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US74365A3095
USD
2.02
-0.04 (-1.94%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationQuarterly Results
Results Snapshot
YoYQoQ
Figures in Million
Consolidate Quarterly Results
Mar'26
Dec'25
Sep'25
Jun'25
Mar'25
Dec'24
Sep'24
Net Sales
33.75
9.12
17.85
15.66
10.11
18.22
17.96
Other Operating Income
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Total Operating income
33.75
9.12
17.85
15.66
10.11
18.22
17.96
Raw Material Cost
4.13
4.62
8.32
5.87
8.18
3.89
8.38
Purchase of Finished goods
0.00
0.00
0.00
0.00
0.00
0.00
0.00
(Increase) / Decrease In Stocks
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Employee Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Power Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Manufacturing Expenses
0.19
0.38
0.18
0.78
0.01
0.01
0.30
Selling and Distribution Expenses
3.05
3.53
2.93
2.62
2.60
3.00
2.60
Other Expenses
0.52
0.53
0.43
0.52
0.35
0.41
0.27
Total Expenditure (Excl Depreciation)
12.60
13.78
15.72
14.49
14.26
11.01
13.97
Operating Profit (PBDIT) excl Other Income
21.099999999999998
-4.699999999999999
2.1
1.2
-4.1
7.199999999999999
4
Other Income
0.19
0.27
0.29
0.27
0.42
0.11
0.15
Operating Profit (PBDIT)
21.74
-4.01
2.79
1.80
-3.38
7.66
4.47
Interest
0.19
0.38
0.18
0.78
0.01
0.01
0.30
Exceptional Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Gross Profit (PBDT)
29.62
4.50
9.53
9.79
1.93
14.33
9.58
Depreciation
0.40
0.39
0.37
0.36
0.35
0.33
0.33
Profit Before Tax
21.14
-4.78
2.24
0.66
-3.73
7.32
3.84
Tax
2.82
0.73
-0.12
0.50
-0.11
0.82
0.61
Provisions and contingencies
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Profit After Tax
18.32
-5.50
2.35
0.16
-3.62
6.49
3.24
Extraordinary Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Net Profit
18.32
-5.50
2.35
0.16
-3.62
6.49
3.24
Share in Profit of Associates
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Minority Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other related items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Consolidated Net Profit
18.32
-5.50
2.35
0.16
-3.62
6.49
3.24
Equity Capital
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Face Value
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Reserves
67.23
48.23
52.91
49.90
45.21
43.21
32.44
Earnings per share (EPS)
0.22
-0.07
0.03
0.0
-0.05
0.09
0.03
Diluted Earnings per share
0.22
-0.07
0.03
0.0
-0.05
0.09
0.03
Operating Profit Margin (Excl OI)
62.65%
-51.06%
11.94%
7.48%
-40.99%
39.57%
22.22%
Gross Profit Margin
63.84%
-48.11%
14.63%
6.52%
-33.48%
41.99%
23.23%
PAT Margin
54.27%
-60.34%
13.19%
1.05%
-35.79%
35.65%
18.02%
Public Share Holdings (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Pledged Promotor Holding (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Quarterly Analysis Highlights - QoQ
stock-summary

Net Sales

QoQ Growth in quarter ended Mar 2026 is 271.43% vs -49.16% in Dec 2025

stock-summary

Consolidate Net Profit

QoQ Growth in quarter ended Mar 2026 is 432.73% vs -329.17% in Dec 2025

stock-summary

Operating Profit (PBDIT) excl Other Income

QoQ Growth in quarter ended Mar 2026 is 602.33% vs -272.00% in Dec 2025

stock-summary

Interest

QoQ Growth in quarter ended Mar 2026 is -50.00% vs 100.00% in Dec 2025

stock-summary

Operating Profit Margin (Excl OI)

QoQ Growth in quarter ended Mar 2026 has improved from Dec 2025

Compare Quarterly Results Of Protalix Biotherapeutics, Inc. With
Markets Mojo
Figures in Million
Consolidate Quarterly Results
Markets Mojo
Markets Mojo
Change(USD)
Change(%)
Net Sales
33.75
0.00
33.75
Other Operating Income
0.00
0.00
0.00
Total Operating income
33.75
0.00
33.75
Raw Material Cost
4.13
0.96
3.17
330.21%
Purchase of Finished goods
0
0
0.00
(Increase) / Decrease In Stocks
0
0
0.00
Employee Cost
0.00
15.27
-15.27
-100.00%
Power Cost
0
0
0.00
Manufacturing Expenses
0.19
0.00
0.19
Selling and Distribution Expenses
3.05
9.31
-6.26
-67.24%
Other Expenses
0.52
2.05
-1.53
-74.63%
Total Expenditure (Excl Depreciation)
12.60
46.05
-33.45
-72.64%
Operating Profit (PBDIT) excl Other Income
21.15
-46.05
67.20
145.93%
Other Income
0.19
1.91
-1.72
-90.05%
Operating Profit (PBDIT)
21.74
-43.18
64.92
150.35%
Interest
0.19
0.00
0.19
Exceptional Items
0.00
0.00
0.00
Gross Profit (PBDT)
29.62
-0.96
30.58
3,185.42%
Depreciation
0.40
0.96
-0.56
-58.33%
Profit Before Tax
21.14
-44.14
65.28
147.89%
Tax
2.82
0.00
2.82
Provisions and contingencies
0
0
0.00
Profit After Tax
18.32
-44.14
62.46
141.50%
Extraordinary Items
0.00
0.00
0.00
Prior Period Expenses
0
0
0.00
Other Adjustments
0
0
0.00
Net Profit
18.32
-44.14
62.46
141.50%
Share in Profit of Associates
0
0
0.00
Minority Interest
0.00
0.00
0.00
Other related items
0.00
0.00
0.00
Consolidated Net Profit
18.32
-44.14
62.46
141.50%
Equity Capital
0
0
0.00
Face Value
0.00
0.00
0.00
Reserves
67.23
204.53
-137.30
-67.13%
Earnings per share (EPS)
0.22
-0.23
0.45
195.65%
Diluted Earnings per share
0.22
-0.23
0.45
195.65%
Operating Profit Margin (Excl OI)
62.65%
0.00%
0.00
62.65%
Gross Profit Margin
63.84%
0.00%
0.00
63.84%
PAT Margin
54.27%
0.00%
0.00
54.27%
Public Share Holdings (%)
0%
0%
0.00
0.00%
Pledged Promotor Holding (%)
0%
0%
0.00
0.00%
Quarterly - Net Sales
Net Sales 3.38 Million
in Mar 2026

Figures in Million
stock-summary

QoQ Growth in quarter ended Mar 2026 is 271.43% vs -49.16% in Dec 2025

stock-summary

YoY Growth in quarter ended Mar 2026 is 234.65% vs 172.97% in Mar 2025

Quarterly - Consolidate Net Profit
Consolidate Net Profit 1.83 Million
in Mar 2026

Figures in Million
stock-summary

QoQ Growth in quarter ended Mar 2026 is 432.73% vs -329.17% in Dec 2025

stock-summary

YoY Growth in quarter ended Mar 2026 is 608.33% vs 21.74% in Mar 2025

Quarterly - Operating Profit (PBDIT)
Operating Profit (PBDIT) 2.16 Million
in Mar 2026

Figures in Million
stock-summary

QoQ Growth in quarter ended Mar 2026 is 602.33% vs -272.00% in Dec 2025

stock-summary

YoY Growth in quarter ended Mar 2026 is 668.42% vs 15.56% in Mar 2025

Quarterly - Interest
Interest 0.02 Million
in Mar 2026

Figures in Million
stock-summary

QoQ Growth in quarter ended Mar 2026 is -50.00% vs 100.00% in Dec 2025

stock-summary

YoY Growth in quarter ended Mar 2026 is 0.00% vs -100.00% in Mar 2025

Quarterly - Operating Profit Margin (Excl OI)
Operating Profit Margin (Excl OI) 62.65%
in Mar 2026

Figures in %
stock-summary

QoQ Growth in quarter ended Mar 2026 has improved from Dec 2025

stock-summary

YoY Growth in quarter ended Mar 2026 has improved from Mar 2025